Non-high density lipoprotein-cholesterol is an indicator to assess cardiovascular risk for subjects with dyslipidemia

doi:10.3969/j.issn.1006-7795.2014.01.016

Abstract

Abstract:

Objective To confirm that non-high density lipoprotein-cholesterol (non-HDL-C) is an effective clinical indicator to assess the cardiovascular disease (CVD) risk and lipid-lowering therapy regardless of glucose level. Methods A total of 6 341 subjects were selected from large-scale clinical survey of the Department of Endocrinology, Beijing Tongren Hospital in 2007. Fasting blood samples were collected from each subject and were tested for total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), HDL-C, triglyceride (TG) and non-HDL-C was calculated by subtracting TC from HDL-C. The subjects were divided into euglycemia group and hyperglycemia group according to fasting glucose level and the other parameters of the 2 groups were compared. Results TC, LDL-C, HDL-C, TG and non-HDL-C in hyperglycemia group were higher than that in euglycemia group. A linear positive correlation was found between non-HDL-C and LDL-C, non-HDL-C and TG. Conclusion non-HDL-C is an effective clinical indicator to assess the cardiovascular decease risk and lipid-lowering therapy.

Key words: non-high density lipoprotein-cholesterol, low density lipoprotein-cholesterol, dyslipidemia, hyperglycemia

CLC Number:

R543

Zhang Pengrui, Xu Yuan, Wang Guang, Yang Jinkui. Non-high density lipoprotein-cholesterol is an indicator to assess cardiovascular risk for subjects with dyslipidemia[J]. Journal of Capital Medical University, 2014, 35(1): 73-76.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2014.01.016

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2014/V35/I1/73

References

[1] Expert Panel on Dection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program(NCEP)Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults(adult treatment panel Ⅲ)[J].JAMA, 2001, 285(19):2486-2497.

[2] 李健斋.非高密度脂蛋白胆固醇——新提出的降脂治疗第二目标[J].临床检验杂志, 2004, 22(1):1-2.

[3] 方圻, 王钟林, 宁田海, 等. 血脂异常防治建议[J]. 中华心血管病杂志, 1997, 25(3):169-172.

[4] 赵志诚.阿托伐他汀治疗老年冠心病合并血脂异常32例[J].中国煤炭工业医学杂志, 2012, 15(6):879.

[5] 王芊, 华川, 郭旭, 等.同型半胱氨酸等危险因子与冠心病的相关性分析[J].临床误诊误治, 2012, 25(3):42-44.

[6] 张润军, 杨丽霞.冠心病危险因素与冠状动脉病变的相关性分析[J].解放军医药杂志, 2011, 23(1):7-11.

[7] Grundy S M. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome[J]. Am J Cardiol, 1998, 81(4A):18B-25B.

[8] Havel R J. Role of triglyceride-rich lipoproteins in progression of atherosclerosis[J]. Circulation, 1990, 81(2):694-696.

[9] Iso H, Naito Y, Sato S, et al. Serum triglycerides and risk of coronary heart disease among Japanese men and women[J]. Am J Epidemiol, 2001, 153(5):490-499.

[10] Yamamoto A, Richie G, Nakamura H, et al. Risk factors for coronary heart disease in the Japanese comparison of the background of patients with acute coronary syndrome in the ASPAC study with data obtained from the general population. Asia-Pacific Collaboration on CHD Risk Factor Intervention study[J]. J Atheroscler Thromb, 2002, 9(4):191-199.

[11] Grundy S M. Non-high-density lipoprotein cholesterol level as potential risk predictor and therapy target[J]. Arch Intern Med, 2001, 161(11):1379-1380.

[12] Packard C J, Saito Y. Non-HDL cholesterol as a measure of atherosclerotic risk[J]. J Atheroscler Thromb, 2004, 11(1):6-14.

[13] Liu J, Sempos C T, Donahue R P, et al. Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease[J]. Am J Cardiol, 2006, 98(10):1363-1368.

[14] Vega G L, Grundy S M. Does measurement of apolipoprotein B have a place in cholesterol management?[J]. Arteriosclerosis, 1990, 10(5):668-671.